German Court Invalidates Omega-3 Drug Patent

Law360, New York (November 27, 2007, 12:00 AM EST) -- A German patent court has ruled that a patent held by Norwegian pharmaceutical company Pronova BioPharma ASA for the active ingredient in its prescription drug Omacor is invalid, the company said Tuesday.

The drug, which is marketed in the United States as Lovaza, is derived from omega-3 fatty acids and is prescribed for the treatment of very high triglyceride levels in adults. It is the first and only omega-3 derived prescription drug approved by the European Union and the U.S. Food and Drug Administration.

Pronova launched...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.